These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38758372)

  • 1. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
    Yin X; Liu X; Ren F; Meng X
    Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
    Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
    J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
    Zhang B; Liu H; Shi C; Gao Z; Zhong R; Gu A; Chu T; Wang H; Xiong L; Zhang W; Zhang X; Yan B; Teng J; Wang W; Bai H; Qiao R; Cheng L; Kuang Y; Zhao R; Zhong H; Han B
    BMC Cancer; 2024 Jun; 24(1):715. PubMed ID: 38862908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
    Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
    Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy.
    Yu L; Hu Y; Xu J; Qiao R; Zhong H; Han B; Xia J; Zhong R
    Int J Cancer; 2023 Aug; 153(3):635-643. PubMed ID: 37078587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers.
    An T; Hui Q; Zong H; Liu L; Cao X; Li R; Hu S; Liu Y; Li J; Zhao R
    Clin Transl Oncol; 2024 Aug; 26(8):2006-2019. PubMed ID: 38530557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
    Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
    Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
    Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
    Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
    Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study.
    Zhang S; Yang L; Yang Y; Yang G; Xu H; Niu X; Wang Y
    Cancer Med; 2023 Oct; 12(19):19438-19448. PubMed ID: 37723846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer.
    Ying X; Shi Z; Shao R; You G; Song Z
    Neoplasma; 2024 Jun; 71(3):297-305. PubMed ID: 38958712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
    Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
    Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
    Front Immunol; 2021; 12():731546. PubMed ID: 34484242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases.
    Xu M; Shao K; Wang Y; Hao Y; Song Z
    Clin Transl Oncol; 2024 Jul; 26(7):1687-1695. PubMed ID: 38363527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.